Cover -- Half Title Page, Title Page, Copyright -- Contents -- Preface: On a Personal Note -- Acknowledgments -- Introduction -- 1. Troubled Sight: Anatomy of the Modern Racial Optic -- 2. Sacred Sight: Anatomy of the Icon -- 3. Iconic Saint, Anti-Iconic Jew -- 4. Colonialism and the Making of New Christendom -- 5. Making Americans: Reading, Reforming, and Redeeming the Immigrant Body -- 6. Jesus: Icon of God -- Conclusion -- Notes -- Bibliography -- Index.
Zugriffsoptionen:
Die folgenden Links führen aus den jeweiligen lokalen Bibliotheken zum Volltext:
Aim: Several lines of evidence from various scientific approaches indicate that alcohol dependence (AD) in humans is genetically influenced. The aim of this review is to report recent findings, new approaches and developments in revealing the genetic underpinnings of alcohol dependence in humans. Results: Results mainly from marker-dependent studies (linkage, case-control association and genome-wide association) and intermediate phenotypes (endophenotypes) are reported as well as findings from recent pharmacogenomic and epigenetic research on alcohol use disorders. Based on the findings, potential perspectives for future research are discussed.
Abstract. Introduction: With advances in medicine, our understanding of diseases has deepened and diagnostic criteria have evolved. Currently, the most frequently used diagnostic systems are the ICD (International Classification of Diseases) and the DSM (Diagnostic and Statistical Manual of Mental Disorders) to diagnose alcohol-related disorders. Results: In this narrative review, we follow the historical developments in ICD and DSM with their corresponding milestones reflecting the scientific research and medical considerations of their time. The current diagnostic concepts of DSM-5 and ICD-11 and their development are presented. Lastly, we compare these two diagnostic systems and evaluate their practicability in clinical use.
"Racism feeds on denial. Lament moves us to tell the truth. And the truth can set us free. Stories of racial injustice fill our news feeds. Yet for too long many in the church have been hesitant to speak up about racism in its many forms. We fear offending others, of using the wrong words, of not knowing what to say. In Lamenting Racism, a team of leading pastors and theologians invite us into the transformative and motivating practice of biblical lament as a powerful way to confront racism. Through their conversations in six thought-provoking videos, they name that God's people of every race are called to consider how we have been shaped and formed by race, and they guide us into experiencing lament as an anti-racism practice. Encouraging congregations to reclaim the lost art of biblical lament, these pastors and theologians model a powerful way to pour out the fear, shame, grief, and rage of racism as we cry out to God in prayer. In the process, we will be transformed and motivated to reclaim hope and to act for a world shaped by God's inclusive vision of love and blessing. The Lamenting Racism Participant Journal guides you through learning the practice of biblical lament as a powerful tool in the church's struggle against racism"--
In: Alcohol and alcoholism: the international journal of the Medical Council on Alcoholism (MCA) and the journal of the European Society for Biomedical Research on Alcoholism (ESBRA), Band 50, Heft 6, S. 690-699
In: Côté , P , Boyle , E , Shearer , H M , Stupar , M , Jacobs , C , Cassidy , J D , Carette , S , van der Velde , G , Wong , J J , Hogg-Johnson , S , Ammendolia , C , Hayden , J A , van Tulder , M & Frank , J W 2019 , ' Is a government-regulated rehabilitation guideline more effective than general practitioner education or preferred-provider rehabilitation in promoting recovery from acute whiplash-associated disorders? A pragmatic randomised controlled trial ' , BMJ Open , vol. 9 , no. 1 , e021283 . https://doi.org/10.1136/bmjopen-2017-021283
OBJECTIVE: To evaluate the effectiveness of a government-regulated rehabilitation guideline compared with education and activation by general practitioners, and to a preferred-provider insurance-based rehabilitation programme on self-reported global recovery from acute whiplash-associated disorders (WAD) grade I-II. DESIGN: Pragmatic randomised clinical trial with blinded outcome assessment. SETTING: Multidisciplinary rehabilitation clinics and general practitioners in Ontario, Canada. PARTICIPANTS: 340 participants with acute WAD grade I and II. Potential participants were sampled from a large automobile insurer when reporting a traffic injury. INTERVENTIONS: Participants were randomised to receive one of three protocols: government-regulated rehabilitation guideline, education and activation by general practitioners or a preferred-provider insurance-based rehabilitation. PRIMARY AND SECONDARY OUTCOME MEASURES: Our primary outcome was time to self-reported global recovery. Secondary outcomes included time on insurance benefits, neck pain intensity, whiplash-related disability, health-related quality of life and depressive symptomatology at 6 weeks and 3, 6, 9 and 12 months postinjury. RESULTS: The median time to self-reported global recovery was 59 days (95% CI 55 to 68) for the government-regulated guideline group, 105 days (95% CI 61 to 126) for the preferred-provider group and 108 days (95% CI 93 to 206) for the general practitioner group; the difference was not statistically significant (Χ2=3.96; 2 df: p=0.138). We found no clinically important differences between groups in secondary outcomes. Post hoc analysis suggests that the general practitioner (hazard rate ratio (HRR)=0.51, 95% CI 0.34 to 0.77) and preferred-provider groups (HRR=0.67, 95% CI 0.46 to 0.96) had slower recovery than the government-regulated guideline group during the first 80 days postinjury. No major adverse events were reported. CONCLUSIONS: Time-to-recovery did not significantly differ across intervention groups. We found no differences between groups with regard to neck-specific outcomes, depression and health-related quality of life. TRIAL REGISTRATION NUMBER: NCT00546806.
In: Côté , P , Boyle , E , Shearer , H M , Stupar , M , Jacobs , C , Cassidy , J D , Carette , S , Van Der Velde , G , Wong , J J , Hogg-Johnson , S , Ammendolia , C , Hayden , J A , Van Tulder , M & Frank , J W 2019 , ' Is a government-regulated rehabilitation guideline more effective than general practitioner education or preferred-provider rehabilitation in promoting recovery from acute whiplash-associated disorders? A pragmatic randomised controlled trial ' , BMJ Open , vol. 9 , no. 1 , e021283 . https://doi.org/10.1136/bmjopen-2017-021283
Objective To evaluate the effectiveness of a government-regulated rehabilitation guideline compared with education and activation by general practitioners, and to a preferred-provider insurance-based rehabilitation programme on self-reported global recovery from acute whiplash-associated disorders (WAD) grade I-II. Design Pragmatic randomised clinical trial with blinded outcome assessment. Setting Multidisciplinary rehabilitation clinics and general practitioners in Ontario, Canada. Participants 340 participants with acute WAD grade I and II. Potential participants were sampled from a large automobile insurer when reporting a traffic injury. Interventions Participants were randomised to receive one of three protocols: Government-regulated rehabilitation guideline, education and activation by general practitioners or a preferred-provider insurance-based rehabilitation. Primary and secondary outcome measures Our primary outcome was time to self-reported global recovery. Secondary outcomes included time on insurance benefits, neck pain intensity, whiplash-related disability, health-related quality of life and depressive symptomatology at 6 weeks and 3, 6, 9 and 12 months postinjury. Results The median time to self-reported global recovery was 59 days (95% CI 55 to 68) for the government-regulated guideline group, 105 days (95% CI 61 to 126) for the preferred-provider group and 108 days (95% CI 93 to 206) for the general practitioner group; the difference was not statistically significant (X 2 =3.96; 2 df: P=0.138). We found no clinically important differences between groups in secondary outcomes. Post hoc analysis suggests that the general practitioner (hazard rate ratio (HRR)=0.51, 95% CI 0.34 to 0.77) and preferred-provider groups (HRR=0.67, 95% CI 0.46 to 0.96) had slower recovery than the government-regulated guideline group during the first 80 days postinjury. No major adverse events were reported. Conclusions Time-to-recovery did not significantly differ across intervention groups. We found no differences between groups with regard to neck-specific outcomes, depression and health-related quality of life.
AIMS: There is increasing evidence showing the importance of long‐acting injectable antipsychotics in the management of schizophrenia, especially in terms of improving patient medication compliance. A panel of experienced clinicians in Hong Kong mapped out a set of consensus statements with an aim to facilitate the understanding and use of long‐acting injectable antipsychotics among local physicians. METHODS: Eight discussion areas regarding long‐acting injectable antipsychotics were selected by the chairman of the consensus group. A series of meetings were held for the panelists to discuss the published literature and their clinical experience, followed by the drafting of consensus statements. At the final meeting, each consensus statement was voted on anonymously by all members based on its practicability of recommendation in Hong Kong. RESULTS: A total of 12 consensus statements on the rational use of long‐acting injectable antipsychotics were established and accepted by the consensus group. CONCLUSION: The consensus statements aim to provide practical guidance for Hong Kong physicians on the use of long‐acting injectable antipsychotics in schizophrenia patients. These statements may also serve as a reference for doctors in other parts of the Asia–Pacific region.
In: Côté , P , Hartvigsen , J , Leboeuf-Yde , C , Corso , M , Shearer , H , Wong , J , Marchand , A-A , French , S , Kawchuk , G N , Mior , S , Poulsen , E , Srbely , J , Ammendolia , C , Blanchette , M-A , Busse , J W , Bussières , A , Cancelliere , C , Christensen , H W , De Carvalho , D , De Luca , K , Du Rose , A , Eklund , A , Engel , R , Goncalves , G , Hebert , J , Hincapié , C A , Kimpton , A , Lauridsen , H H , Innes , S , Meyer , A-L , Newell , D , O'Neill , S , Pagé , I , Passmore , S , Perle , S M , Quon , J , Rezai , M , Stupar , M , Swain , M , Vitello , A , Weber , K , Young , K J & Yu , H 2021 , ' The global summit on the efficacy and effectiveness of spinal manipulative therapy for the prevention and treatment of non-musculoskeletal disorders: a systematic review of the literature ' , Chiropractic & Manual Therapies , vol. 29 , 8 . https://doi.org/10.1186/s12998-021-00362-9
Background: A small proportion of chiropractors, osteopaths, and other manual medicine providers use spinal manipulative therapy (SMT) to manage non-musculoskeletal disorders. However, the efficacy and effectiveness of these interventions to prevent or treat non-musculoskeletal disorders remain controversial. Objectives: We convened a Global Summit of international scientists to conduct a systematic review of the literature to determine the efficacy and effectiveness of SMT for the primary, secondary and tertiary prevention of non-musculoskeletal disorders. Global summit: The Global Summit took place on September 14–15, 2019 in Toronto, Canada. It was attended by 50 researchers from 8 countries and 28 observers from 18 chiropractic organizations. At the summit, participants critically appraised the literature and synthesized the evidence. Systematic review of the literature: We searched MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, the Cumulative Index to Nursing and Allied Health, and the Index to Chiropractic Literature from inception to May 15, 2019 using subject headings specific to each database and free text words relevant to manipulation/manual therapy, effectiveness, prevention, treatment, and non-musculoskeletal disorders. Eligible for review were randomized controlled trials published in English. The methodological quality of eligible studies was assessed independently by reviewers using the Scottish Intercollegiate Guidelines Network (SIGN) criteria for randomized controlled trials. We synthesized the evidence from articles with high or acceptable methodological quality according to the Synthesis without Meta-Analysis (SWiM) Guideline. The final risk of bias and evidence tables were reviewed by researchers who attended the Global Summit and 75% (38/50) had to approve the content to reach consensus. Results: We retrieved 4997 citations, removed 1123 duplicates and screened 3874 citations. Of those, the eligibility of 32 articles was evaluated at the Global Summit and 16 articles were included in our systematic review. Our synthesis included six randomized controlled trials with acceptable or high methodological quality (reported in seven articles). These trials investigated the efficacy or effectiveness of SMT for the management of infantile colic, childhood asthma, hypertension, primary dysmenorrhea, and migraine. None of the trials evaluated the effectiveness of SMT in preventing the occurrence of non-musculoskeletal disorders. Consensus was reached on the content of all risk of bias and evidence tables. All randomized controlled trials with high or acceptable quality found that SMT was not superior to sham interventions for the treatment of these non-musculoskeletal disorders. Six of 50 participants (12%) in the Global Summit did not approve the final report. Conclusion: Our systematic review included six randomized clinical trials (534 participants) of acceptable or high quality investigating the efficacy or effectiveness of SMT for the treatment of non-musculoskeletal disorders. We found no evidence of an effect of SMT for the management of non-musculoskeletal disorders including infantile colic, childhood asthma, hypertension, primary dysmenorrhea, and migraine. This finding challenges the validity of the theory that treating spinal dysfunctions with SMT has a physiological effect on organs and their function. Governments, payers, regulators, educators, and clinicians should consider this evidence when developing policies about the use and reimbursement of SMT for non-musculoskeletal disorders.
Abstract Background A small proportion of chiropractors, osteopaths, and other manual medicine providers use spinal manipulative therapy (SMT) to manage non-musculoskeletal disorders. However, the efficacy and effectiveness of these interventions to prevent or treat non-musculoskeletal disorders remain controversial. Objectives We convened a Global Summit of international scientists to conduct a systematic review of the literature to determine the efficacy and effectiveness of SMT for the primary, secondary and tertiary prevention of non-musculoskeletal disorders. Global summit The Global Summit took place on September 14–15, 2019 in Toronto, Canada. It was attended by 50 researchers from 8 countries and 28 observers from 18 chiropractic organizations. At the summit, participants critically appraised the literature and synthesized the evidence. Systematic review of the literature We searched MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, the Cumulative Index to Nursing and Allied Health, and the Index to Chiropractic Literature from inception to May 15, 2019 using subject headings specific to each database and free text words relevant to manipulation/manual therapy, effectiveness, prevention, treatment, and non-musculoskeletal disorders. Eligible for review were randomized controlled trials published in English. The methodological quality of eligible studies was assessed independently by reviewers using the Scottish Intercollegiate Guidelines Network (SIGN) criteria for randomized controlled trials. We synthesized the evidence from articles with high or acceptable methodological quality according to the Synthesis without Meta-Analysis (SWiM) Guideline. The final risk of bias and evidence tables were reviewed by researchers who attended the Global Summit and 75% (38/50) had to approve the content to reach consensus. Results We retrieved 4997 citations, removed 1123 duplicates and screened 3874 citations. Of those, the eligibility of 32 articles was evaluated at the Global Summit and 16 articles were included in our systematic review. Our synthesis included six randomized controlled trials with acceptable or high methodological quality (reported in seven articles). These trials investigated the efficacy or effectiveness of SMT for the management of infantile colic, childhood asthma, hypertension, primary dysmenorrhea, and migraine. None of the trials evaluated the effectiveness of SMT in preventing the occurrence of non-musculoskeletal disorders. Consensus was reached on the content of all risk of bias and evidence tables. All randomized controlled trials with high or acceptable quality found that SMT was not superior to sham interventions for the treatment of these non-musculoskeletal disorders. Six of 50 participants (12%) in the Global Summit did not approve the final report. Conclusion Our systematic review included six randomized clinical trials (534 participants) of acceptable or high quality investigating the efficacy or effectiveness of SMT for the treatment of non-musculoskeletal disorders. We found no evidence of an effect of SMT for the management of non-musculoskeletal disorders including infantile colic, childhood asthma, hypertension, primary dysmenorrhea, and migraine. This finding challenges the validity of the theory that treating spinal dysfunctions with SMT has a physiological effect on organs and their function. Governments, payers, regulators, educators, and clinicians should consider this evidence when developing policies about the use and reimbursement of SMT for non-musculoskeletal disorders.
In: Côté , P , Bussières , A , Cassidy , J D , Hartvigsen , J , Kawchuk , G N , Leboeuf-Yde , C , Mior , S , Schneider , M , Aillet , L , Ammendolia , C , Arnbak , B , Axen , I , Baechler , M , Barbier-Cazorla , F , Barbier , G , Bergstrøm , C , Beynon , A , Blanchette , M A , Bolton , P S , Breen , A , Brinch , J , Bronfort , G , Brown , B , Bruno , P , Konner , M B , Burrell , C , Busse , J W , Byfield , D , Campello , M , Cancelliere , C , Carroll , L , Cedraschi , C , Chéron , C , Chow , N , Christensen , H W , Claussen , S , Corso , M , Davis , M A , Demortier , M , De Carvalho , D , De Luca , K , De Zoete , A , Doktor , K , Downie , A , Du Rose , A , Eklund , A , Engel , R , Erwin , M , Eubanks , J E , Evans , R , Evans , W , Fernandez , M , Field , J , Fournier , G , French , S , Fuglkjaer , S , Gagey , O , Giuriato , R , Gliedt , J A , Goertz , C , Goncalves , G , Grondin , D , Gurden , M , Haas , M , Haldeman , S , Harsted , S , Hartvigsen , L , Hayden , J , Hincapié , C , Hébert , J J , Hesby , B , Hestbæk , L , Hogg-Johnson , S , Hondras , M A , Honoré , M , Howarth , S , Injeyan , H S , Innes , S , Irgens , P M , Jacobs , C , Jenkins , H , Jenks , A , Jensen , T S , Johhansson , M , Kongsted , A , Kopansky-Giles , D , Kryger , R , Lardon , A , Lauridsen , H H , Leininger , B , Lemeunier , N , Le Scanff , C , Lewis , E A , Linaker , K , Lothe , L , Marchand , A A , McNaughton , D , Meyer , A L , Miller , P , Mølgaard , A , Moore , C , Murphy , D R , Myburgh , C , Myhrvold , B , Newell , D , Newton , G , Nim , C , Nordin , M , Nyiro , L , O'Neill , S , Øverås , C , Pagé , I , Pasquier , M , Penza , C W , Perle , S M , Picchiottino , M , Piché , M , Poulsen , E , Quon , J , Raven , T , Rezai , M , Roseen , E J , Rubinstein , S , Salmi , L R , Schweinhardt , P , Shearer , H M , Sirucek , L , Sorondo , D , Stern , P J , Stevans , J , Stochkendahl , M J , Stuber , K , Stupar , M , Srbely , J , Swain , M , Teodorczyk-Injeyan , J , Théroux , J , Thiel , H , Uhrenholt , L , Verbeek , A , Verville , L , Vincent , K , Dan Wang , A L , Weber , K A , Whedon , J M , Wong , J , Wuytack , F , Young , J , Yu , H & Ziegler , D 2020 , ' A united statement of the global chiropractic research community against the pseudoscientific claim that chiropractic care boosts immunity ' , Chiropractic and Manual Therapies , vol. 28 , no. 1 , 21 . https://doi.org/10.1186/s12998-020-00312-x
Background: In the midst of the coronavirus pandemic, the International Chiropractors Association (ICA) posted reports claiming that chiropractic care can impact the immune system. These claims clash with recommendations from the World Health Organization and World Federation of Chiropractic. We discuss the scientific validity of the claims made in these ICA reports. Main body: We reviewed the two reports posted by the ICA on their website on March 20 and March 28, 2020. We explored the method used to develop the claim that chiropractic adjustments impact the immune system and discuss the scientific merit of that claim. We provide a response to the ICA reports and explain why this claim lacks scientific credibility and is dangerous to the public. More than 150 researchers from 11 countries reviewed and endorsed our response. Conclusion: In their reports, the ICA provided no valid clinical scientific evidence that chiropractic care can impact the immune system. We call on regulatory authorities and professional leaders to take robust political and regulatory action against those claiming that chiropractic adjustments have a clinical impact on the immune system.